View Exam | PowerPak

1. According to the American Urological Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (AUA/SUFU) overactive bladder (OAB) treatment guidelines, the use of combination therapy with an antimuscarinic and beta-3 agonist is appropriate:

A. After a failed response to beta-3 agonist monotherapy B. After at least two failed responses to monotherapy C. Only after a 2-week trial of antimuscarinic monotherapy D. With inadequate response to behavioral therapy, with or without an oral medication

2. Concomitant use of multiple medications with anticholinergic activity may increase the risk of:

A. Insomnia B. Falls/fractures C. Diarrhea D. Bradycardia

3. A 72-year-old male patient continues to experience urinary frequency, urgency, and nocturia. His current medications include donepezil and losartan. In addition to behavioral therapy, what do you recommend?

A. Oxybutynin immediate release (IR) B. Tolterodine IR C. Trospium IR D. Mirabegron

4. Vibegron, in contrast to mirabegron, does not inhibit:

A. CYP1A2 B. CYP2C8 C. CYP2D6 D. CYP3A4

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. According to the American Urological Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (AUA/SUFU) overactive bladder (OAB) treatment guidelines, the use of combination therapy with an antimuscarinic and beta-3 agonist is appropriate:

2. Concomitant use of multiple medications with anticholinergic activity may increase the risk of:

3. A 72-year-old male patient continues to experience urinary frequency, urgency, and nocturia. His current medications include donepezil and losartan. In addition to behavioral therapy, what do you recommend?

4. Vibegron, in contrast to mirabegron, does not inhibit:

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. According to the American Urological Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (AUA/SUFU) overactive bladder (OAB) treatment guidelines, the use of combination therapy with an antimuscarinic and beta-3 agonist is appropriate:

2. Concomitant use of multiple medications with anticholinergic activity may increase the risk of:

3. A 72-year-old male patient continues to experience urinary frequency, urgency, and nocturia. His current medications include donepezil and losartan. In addition to behavioral therapy, what do you recommend?

4. Vibegron, in contrast to mirabegron, does not inhibit:

« Return to Activity

Customers who Purchased
this Activity also Purchased